Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results
Pulmonx Corporation (LUNG)
US:NASDAQ Investor Relations:
investor.prolunginc.com/investor-relations
Company Research
Source: GlobeNewswire
REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year of 2023 ended December 31, 2023. Recent Highlights Delivered $68.7 million in worldwide revenue for the full year of 2023, a 28% increase over the prior yearAchieved record worldwide revenue of $19.3 million for the fourth quarter of 2023, a 25% increase over the same period last year and an increase of 23% in constant currencySet new records of $13.7 million and $45.9 million in U.S. revenue for the fourth quarter 2023 and the full year 2023, representing 45% and 41% year-over-year growth, respectivelyRealized gross margin of 75% in the fourth quarter of 2023 and 74% for the full year of 2023Added 14 new Zephyr Valve U.S. treatment centers in the fourth quarter 2023Received Food and Drug Administration approval to commence CON
Show less
Read more
Impact Snapshot
Event Time:
LUNG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LUNG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LUNG alerts
High impacting Pulmonx Corporation news events
Weekly update
A roundup of the hottest topics
LUNG
News
- Pulmonx GAAP EPS of -$0.36 [Seeking Alpha]Seeking Alpha
- Pulmonx Reports First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Pulmonx Reports First Quarter 2024 Financial ResultsGlobeNewswire
- Pulmonx to Report First Quarter 2024 Financial Results on May 1, 2024GlobeNewswire
- Pulmonx Co. (NASDAQ: LUNG) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $17.00 price target on the stock.MarketBeat
LUNG
Earnings
- 5/1/24 - Beat
LUNG
Sec Filings
- 5/1/24 - Form 8-K
- 4/24/24 - Form 4
- 4/22/24 - Form 144
- LUNG's page on the SEC website